AIMMED is a leading digital therapeutics company based in Seoul, South Korea. As a frontrunner in South Korea’s DTx industry, in the field of mental health and psychiatry. Since 2019, AIMMED has been continuously expanding the product pipeline across a broad-spectrum of disease areas, and trying to discover, develop, and improve software-based therapeutics for creating more effective and personalized products for patients and clinicians. Through cognitive and neurobehavioral mechanisms, AIMMED proves the safety and clinical effectiveness of the evidence-based products to deliver better outcomes for patients across the globe.